MX342907B - El uso de un anticuerpo anti-cd52 monoclonal para el tratamiento de lupus. - Google Patents

El uso de un anticuerpo anti-cd52 monoclonal para el tratamiento de lupus.

Info

Publication number
MX342907B
MX342907B MX2011012048A MX2011012048A MX342907B MX 342907 B MX342907 B MX 342907B MX 2011012048 A MX2011012048 A MX 2011012048A MX 2011012048 A MX2011012048 A MX 2011012048A MX 342907 B MX342907 B MX 342907B
Authority
MX
Mexico
Prior art keywords
methods
compositions
treating lupus
patient
lupus
Prior art date
Application number
MX2011012048A
Other languages
English (en)
Spanish (es)
Other versions
MX2011012048A (es
Inventor
Johanne M Kaplan
Bruce L Roberts
William M Siders
Original Assignee
Genzyme Corp *
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp * filed Critical Genzyme Corp *
Publication of MX2011012048A publication Critical patent/MX2011012048A/es
Publication of MX342907B publication Critical patent/MX342907B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2893—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Microbiology (AREA)
MX2011012048A 2009-05-13 2010-05-13 El uso de un anticuerpo anti-cd52 monoclonal para el tratamiento de lupus. MX342907B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17792409P 2009-05-13 2009-05-13
PCT/US2010/034741 WO2010132683A1 (en) 2009-05-13 2010-05-13 Methods and compositions for treating lupus

Publications (2)

Publication Number Publication Date
MX2011012048A MX2011012048A (es) 2011-12-12
MX342907B true MX342907B (es) 2016-10-17

Family

ID=43085330

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011012048A MX342907B (es) 2009-05-13 2010-05-13 El uso de un anticuerpo anti-cd52 monoclonal para el tratamiento de lupus.

Country Status (12)

Country Link
US (2) US9617343B2 (enExample)
EP (2) EP3345620B1 (enExample)
JP (3) JP5834004B2 (enExample)
KR (1) KR101800467B1 (enExample)
CN (2) CN110179989B (enExample)
AU (2) AU2010248935B2 (enExample)
BR (1) BRPI1013927A2 (enExample)
CA (1) CA2761885A1 (enExample)
IL (1) IL216146A0 (enExample)
MX (1) MX342907B (enExample)
RU (1) RU2607022C2 (enExample)
WO (1) WO2010132683A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011012047A (es) 2009-05-13 2011-12-14 Genzyme Corp Inmunoglobulinas humanas anti-cd52.
WO2013107413A1 (zh) * 2012-01-19 2013-07-25 中国科学院上海巴斯德研究所 磷酸化途径相关因子在调控调节性t细胞功能中的应用
RU2019103573A (ru) * 2013-02-08 2019-03-15 Аллегени-Сингер Рисерч Инститьют Клеточно-связанные продукты активации комплемента в качестве диагностических биомаркеров волчанки в доклинической стадии
AR095199A1 (es) 2013-03-15 2015-09-30 Genzyme Corp Anticuerpos anti-cd52
CA2899835A1 (en) * 2013-03-20 2014-09-25 F. Hoffmann-La Roche Ag Specific detection of rat antibodies in mouse serum
DK3105317T3 (en) * 2014-02-14 2019-01-14 Cellectis Immunotherapy cells that are genetically engineered to target antigen on both immune cells and pathological cells
CA2977106A1 (en) * 2015-02-27 2016-09-01 Icell Gene Therapeutics Llc Chimeric antigen receptors (cars) targeting hematologic malignancies, compositions and methods of use thereof
TWI833684B (zh) 2015-06-25 2024-03-01 美商生物細胞基因治療有限公司 嵌合抗原受體（ｃａｒ）、組合物及其使用方法
US11173179B2 (en) 2015-06-25 2021-11-16 Icell Gene Therapeutics Llc Chimeric antigen receptor (CAR) targeting multiple antigens, compositions and methods of use thereof
CN109562126A (zh) 2016-06-24 2019-04-02 美商生物细胞基因治疗有限公司 嵌合抗原受体(car)、组合物及其使用方法
CN118853581A (zh) 2017-06-21 2024-10-29 美商生物细胞基因治疗有限公司 嵌合抗原受体(CARs)、组合物及其使用方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9022543D0 (en) 1990-10-17 1990-11-28 Wellcome Found Antibody production
GB9022547D0 (en) 1990-10-17 1990-11-28 Wellcome Found Purified immunoglobulin
GB9125768D0 (en) 1991-12-04 1992-02-05 Hale Geoffrey Therapeutic method
US7119248B1 (en) 1994-04-12 2006-10-10 Miltenyi Biotec Gmbh Antibodies against epitopes with homology to self antigens, methods of preparation and applications thereof
US7060802B1 (en) * 2000-09-18 2006-06-13 The Trustees Of Columbia University In The City Of New York Tumor-associated marker
US7465790B2 (en) 2000-10-09 2008-12-16 Isis Innovation, Inc. Therapeutic antibodies
US20050191632A1 (en) * 2002-11-01 2005-09-01 John Byrd Cytogenetic abnormalities that are predictive of response to therapy for chronic lymphocytic leukemia
US7534427B2 (en) 2002-12-31 2009-05-19 Immunomedics, Inc. Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
KR20060002896A (ko) 2003-03-31 2006-01-09 기린 비루 가부시키가이샤 항 ｃｄ52 항체에 의한 조절성 ｔ 세포 분화 유도ㆍ증식방법 및 그를 위한 의약 조성물
EP1694706B1 (en) 2003-11-01 2012-04-04 Merck Patent GmbH Modified anti-cd52 antibody
AU2005249360B2 (en) 2004-04-12 2011-07-21 Medimmune, Llc Anti-IL-9 antibody formulations and uses thereof
CN101443040A (zh) * 2006-03-16 2009-05-27 基因技术股份有限公司 用cd4抗体治疗狼疮的方法
JP2009533350A (ja) 2006-04-07 2009-09-17 キメロス， インコーポレイテッド Ｂ細胞悪性疾患を処置するための組成物および方法
WO2007121233A1 (en) * 2006-04-12 2007-10-25 Genzyme Corporation Methods of treating autoimmune diseases
GB0608054D0 (en) * 2006-04-24 2006-05-31 Isis Innovation Production and use of regulatory t cells
US20100034782A1 (en) * 2006-05-31 2010-02-11 Nader Najafian Methods of Using Anti-Thymocyte Globulin and Related Agents
DK2046809T3 (en) * 2006-07-19 2017-03-13 Univ Pennsylvania WSX-1 / IL-27 AS A TARGET OBJECTIVE FOR ANTI-INFLAMMATORY REACTIONS
EP2102367A2 (en) 2006-11-09 2009-09-23 XDX, Inc. Methods for diagnosing and monitoring the status of systemic lupus erythematosus
MX2011012047A (es) * 2009-05-13 2011-12-14 Genzyme Corp Inmunoglobulinas humanas anti-cd52.
AR095199A1 (es) 2013-03-15 2015-09-30 Genzyme Corp Anticuerpos anti-cd52

Also Published As

Publication number Publication date
EP2429583A4 (en) 2013-10-16
KR101800467B1 (ko) 2017-11-22
MX2011012048A (es) 2011-12-12
CN102438654A (zh) 2012-05-02
US20170369583A1 (en) 2017-12-28
CN110179989B (zh) 2022-06-24
JP2012526846A (ja) 2012-11-01
US20120070408A1 (en) 2012-03-22
US9617343B2 (en) 2017-04-11
CA2761885A1 (en) 2010-11-18
RU2011150495A (ru) 2013-06-20
AU2017201771A1 (en) 2017-04-06
BRPI1013927A2 (pt) 2016-04-05
EP3345620B1 (en) 2024-08-28
CN110179989A (zh) 2019-08-30
RU2607022C2 (ru) 2017-01-10
AU2010248935B2 (en) 2016-12-15
JP2017008106A (ja) 2017-01-12
EP2429583A1 (en) 2012-03-21
JP2015052021A (ja) 2015-03-19
AU2010248935A1 (en) 2011-11-17
IL216146A0 (en) 2012-01-31
WO2010132683A1 (en) 2010-11-18
EP3345620A1 (en) 2018-07-11
JP5834004B2 (ja) 2015-12-16
KR20140014392A (ko) 2014-02-06

Similar Documents

Publication Publication Date Title
MX2011012048A (es) Metodos y composiciones para el tratamiento del lupus.
GB2471588A (en) Therapeutic peptidomimetic macrocycles
JO2828B1 (en) Anti-Hepsidine antibodies and their uses
MY160041A (en) Compositions and methods for treating parasitic infections
PH12017501075A1 (en) Human monoclonal antibody with specificity for dengue virus serotype 1 e protein and uses thereof
MX2009005849A (es) Composiciones y metodos para tratar cancer con adn rico en cpg y cupredoxinas.
SG169327A1 (en) Compositions and methods of use for antibodies of dickkopf-1 and/or -4
SG166093A1 (en) Inhibitors of brutonæs tyrosine kinase
ATE540709T1 (de) Implantierbare medizinische vorrichtung mit partikelbeschichtung
NZ602220A (en) Antibodies with ph dependent antigen binding
MX2011009362A (es) Proteinas de union a il-17.
NZ703668A (en) Complexes of il-15 and il-15ralpha and uses thereof
WO2012081898A3 (ko) 위암의 예후 예측용 마커 및 이를 이용하는 위암의 예후 예측 방법
EA201301180A1 (ru) Основанная на bcma стратификация и терапия пациентов, страдающих множественной миеломой
WO2008034076A3 (en) Cyclophosphamide in combination with immune therapeutics
WO2010132697A3 (en) Methods and compositions for treatment
UA101814C2 (ru) Фактор, задействованный в латентной инфекции герпесвирусом, и его применение
WO2009023333A3 (en) Inhibition of the sh2-domain containing protein tyr-phosphatase, shp-1, to enhance vaccines
PH12012502406A1 (en) Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (lrp6) antibodies
WO2014028668A3 (en) Stem cell enhancing therapeutics
WO2008085962A3 (en) Cell culture methods for producing recombinant proteins in the presence of reduced levels of one or more contaminants
PH12013502194A1 (en) Antibodies to egfl7 and methods for their use
WO2006002377A3 (en) Optimized dosing with anti-cd4 antibodies for tolerance induction in primates
AU2016204146A1 (en) Methods of Increasing Neuronal Differentiation Using Antibodies to Lysophoshatidic Acid
ATE475670T1 (de) Konsensus-peptid

Legal Events

Date Code Title Description
FG Grant or registration